Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Boehringer Ingelheim - Focus on NSCLC treatment options

Live Q&A - 22 September 2020 - 17:00-17:30

Date

14 Sep 2020

Session

Boehringer Ingelheim - Focus on NSCLC treatment options

Presenters

Tanja Cufer

Authors

T. Cufer

Author affiliations

Department Of Medical Oncology, University Clinic Golnik, University of Ljubljana,, 4208 - Golnik/SI

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

14 Sep 2020

Welcome and introduction

Presenter: Tanja Cufer

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

14 Sep 2020

Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma

Presenter: Silvia Novello

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

14 Sep 2020

Uncommon EGFR mutations

Presenter: Xiuning Le

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

14 Sep 2020

The Future of NSCLC

Presenter: Melissa Johnson

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

14 Sep 2020

Key insights and closing remarks

Presenter: Tanja Cufer

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast